Global /South Korea /Healthcare /Biotechnology /185490

EyeGene Inc.

185490

• KRX: 185490 • Delayed

1,449KRW -0.4%

0.9453 USD

As of 5 June 2026, EyeGene Inc. has a market cap of $40.87M USD, ranking #32047 globally and #1888 in South Korea. It ranks #2896 in the Healthcare sector, and #561 in the Biotechnology industry.

Global Rank

32047

Country Rank

1888

Sector Rank

2896

Industry Rank

561

Key Stats

Market Cap

$40.87MUSD

62.64B KRW

Enterprise Value

$10.92MUSD

16.74B KRW

Revenue (TTM)

$2.33MUSD

3.57B KRW

EBITDA (TTM)

-$5.13MUSD

-7.86B KRW

Net Income (TTM)

-$10.25MUSD

-15.71B KRW

EBITDA Margin

-220%

PS Ratio

17.6

PB Ratio

1.1

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Biotechnology

CEO

Won-Il Yoo open_in_new

Founded

2000

Website

eyegene.co.kr open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.4%	-1.4%	-4.6%	-6.4%	-29%	-16%	-55%	-66%	-92%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	185490 아이진(주) ISIN: KR7185490000 Shares Out.: Shares Outstanding: 43.223M¹ Shares Float: 30.635M² TV: TradingView: KRX: 185490 SA: Stock Analysis: KRX: 185490 YF: Yahoo Finance: 185490.KS GF: Google Finance: KRX: 185490 BA: Barron's: 185490 MS: Morningstar: XKRX: 185490	1,449 KRW	TV: TradingView: KRX: 185490 SA: Stock Analysis: KRX: 185490 YF: Yahoo Finance: 185490.KS GF: Google Finance: KRX: 185490 BA: Barron's: 185490 MS: Morningstar: XKRX: 185490

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About EyeGene Inc.

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial. In addition, the company offers vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Similar Companies

Industry: Biotechnology (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 109K%	35.5	South Korea
Celltrion, Inc. KRX: 068270	$27.89B 42.76T KRW 68K%	43.8	South Korea
ALTEOGEN Inc. KRX: 196170	$13.27B 20.33T KRW 32K%	146.6	South Korea
HLB Co., Ltd. KRX: 028300	$5.46B 8.37T KRW 13K%	-	South Korea
Peptron, Inc. KRX: 087010	$3.96B 6.07T KRW 10K%	-	South Korea
SK bioscience Co.,Ltd. KRX: 302440	$2.23B 3.42T KRW 5K%	-	South Korea

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 446K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 391K%	19.0	United States
argenx SE EBR: ARGX	$48.01B 41.39B EUR 117K%	39.9	Netherlands
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 105K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.55B 33.71B CHF 104K%	37.2	Switzerland
Natera, Inc. NASDAQ: NTRA	$27.6B 67K%	-	United States

chevron_leftBack